OIS@ASCRS 2016 Videos
In a packed ballroom at the Intercontinental Hotel, OIS attendees recognized the achievements of one of ophthalmology’s physician-innovators. Roger F. Steinert, MD, was honored as…
Read More
The KAMRA small-aperture corneal inlay from AcuFocus was approved by the FDA in April 2015 for the treatment of presbyopia, and the company began a…
Read More
Ocular Therapeutix expects to hear from the FDA on its PDUFA date of July 24, 2016, on its new drug application for DEXTENZA, its sustained-release…
Read More
Heidelberg Engineering, which has more than 10,000 optical coherence tomography (OCT) units in place worldwide, is looking to help drive the premium channel by entering…
Read More
Phase II results of ForSight Vision5’s bimatoprost ocular ring insert have shown the ring achieves clinically significant reductions in intraocular pressure (IOP) over six months…
Read More
A panel of physicians and corporate leaders discuss the increasingly important impact diagnostics have on the premium channel. Topics included number of tests done, appetite…
Read More
Richard Lindstrom, MD, opened up the Diagnostics-Impact on the Premium Channel with an overview of the market including a look at competitors. Video Highlights 00:37…
Read More
Moving cataract surgery outcomes from 80% of patients within 0.5 D of targeted refraction to 95% requires “a lot of little things,” Karlheinz Rein, PhD,…
Read More
Aerie Pharmaceuticals has completed all patient visits in two Phase III clinical trials of the Rho kinase inhibitor Rhopressa (netarsudil) 0.02% for treatment of glaucoma…
Read More
As cataract patients’ expectations rise, demanding visual performance on par with refractive surgery, Alcon is striving to meet those high expectations through its Cataract Refractive…
Read More
Ike K. Ahmed, MD, led a discussion between three notable ophthalmologists treating glaucoma patients with MIGs. The panel followed a presentation by Ahmed and four…
Read More
TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")